Seres Therapeutics, Inc.

As of July 8, 2024, Seres Therapeutics, Inc. is considered overvalued and has deteriorated to a "does not qualify" rating due to poor financial metrics, including a negative ROCE and ROE, and has underperformed the S&P 500, making it a less appealing investment compared to its peers.

As of August 13, 2024, Seres Therapeutics, Inc. is considered overvalued at $7.42 due to significant financial deterioration, negative profitability metrics, and poor stock performance, with a year-to-date return of -55.35%.

As of June 11, 2025, Seres Therapeutics, Inc. shows a mildly bearish trend, indicated by bearish weekly MACD and KST indicators, daily moving averages, and Bollinger Bands, suggesting weak bearish momentum in the near term.

As of March 2022, the management team of Seres Therapeutics, Inc. includes Independent Chairman Mr. Stephen Berenson, President and CEO Mr. Eric Shaff, and several Independent Directors: Dr. Dennis Ausiello, Mr. Gregory Behar, Mr. Paul Biondi, Dr. Willard Dere, and Mr. Kurt Graves.

Seres Therapeutics, Inc. is a microbiome therapeutics company focused on developing Ecobiotic therapies to restore health by repairing dysbiotic microbiomes. It operates in the Pharmaceuticals & Biotechnology industry with a market cap of approximately $63.92 million.

As of Jun 18, Seres Therapeutics, Inc. has a market capitalization of 63.92 million, with net sales of 0.00 million and a net profit of -66.86 million over the last four quarters. The company reported shareholder's funds of 13.78 million and total assets of 139.81 million as of Dec 24.